论文部分内容阅读
目的微小RNA(microRNA,miRNA)差异表达与多种肿瘤的发生发展密切相关,但微小RNA-187-3p(miR-187-3p)在肝细胞癌(hepatocellular carcinoma,HCC)中的表达及预后意义研究较少。本研究检测HCC组织中microRNA的表达谱,分析miR-187-3p在HCC组织中的表达及其与临床病理特征之间的关系,探讨miR-187-3p表达在其发生、发展及预后中的作用。方法利用microRNA芯片杂交技术筛选5例HCC组织及相应癌旁组织中差异表达的microRNA,然后通过实时荧光定量PCR(real-time fuorescence quantitative-PCR,RFQ-PCR)法验证86例HCC组织及相应癌旁组织中miR-187-3p表达水平,并统计临床病理资料,随访生存期。结果 148个microRNAs在HCC组织中差异表达,其中102个microRNAs在HCC组织较相应癌旁组织表达下调,46个microRNAs在HCC组织较相应癌旁组织表达上调。RFQ-PCR结果显示,miR-187-3p在HCC组织中表达水平明显低于相应癌旁组织,差异有统计学意义,Z=-2.244,P=0.025。HCC中miR-187-3p表达状态与肿瘤大小(χ~2=5.031,P=0.025)相关,而与性别(χ~2=3.648,P=0.056)、年龄(χ~2=0.003,P=0.956)、是否转移(χ~2=0.005,P=0.943)、TNM分期(χ~2=0.129,P=0.719)、肿瘤数目(χ~2=0.126,P=0.722)、乙肝表面抗原(χ~2=0.019,P=0.890)、AFP水平(χ~2=0.187,P=0.665)和Child分级(χ~2=1.665,P=0.197)无关。miR-187-3p低表达的HCC患者总生存期较高表达者明显缩短,χ~2=7.684,P=0.006。且多因素分析发现,miR-187-3p表达水平和TNM分期是影响HCC患者生存预后的独立危险因素。结论 miR-187-3p在一定程度上参与了HCC的发生发展,其有望成为HCC新的潜在的治疗靶点以及诊断、判断病情和预测预后的分子标志物。
The differential expression of microRNA (miRNA) is closely related to the occurrence and development of various tumors. However, the expression and prognostic significance of microRNA-187-3p (miR-187-3p) in hepatocellular carcinoma (HCC) Less research This study examined the expression profile of microRNAs in HCC tissues, analyzed the expression of miR-187-3p in HCC tissues and its relationship with clinicopathological features, and explored the role of miR-187-3p in its development, progression and prognosis effect. Methods MicroRNAs differentially expressed in 5 HCC tissues and corresponding adjacent tissues were screened by microRNA microarray hybridization technique, and 86 HCC tissues and corresponding cancers were identified by real-time quantitative fluorescence quantitative PCR (RFQ-PCR) Next to the organization of miR-187-3p expression levels, and statistical clinical and pathological data, follow-up survival. Results 148 microRNAs were differentially expressed in HCC tissues. Among them, 102 microRNAs were down-regulated in corresponding HCC tissues and adjacent cancerous tissues, and 46 microRNAs were up-regulated in corresponding HCC tissues. The results of RFQ-PCR showed that the expression level of miR-187-3p in HCC tissues was significantly lower than that in paracancerous tissues, with a significant difference (Z = -2.244, P = 0.025). The expression of miR-187-3p in HCC correlated with tumor size (χ ~ 2 = 5.031, P = 0.025), but not with gender (χ ~ 2 = 3.648, (Χ ~ 2 = 0.126, P = 0.722), hepatitis B surface antigen (χ ~ 2 = 0.126, P = 0.943) 2 = 0.019, P = 0.890), AFP level (χ ~ 2 = 0.187, P = 0.665) and Child classification (χ ~ 2 = 1.665, P = 0.197). HCC patients with low expression of miR-187-3p had a significantly shorter overall survival (χ ~ 2 = 7.684, P = 0.006). Multivariate analysis showed that miR-187-3p expression and TNM stage were independent risk factors for prognosis of HCC patients. Conclusion miR-187-3p is involved in the development of HCC to a certain extent. It is expected to be a potential new therapeutic target for HCC and a molecular marker for diagnosis, diagnosis and prediction of prognosis.